Insights on the Japan Bladder Cancer Market to 2026 | Industry Statistics, Emerging Demands, Forecast to 2026

Japan bladder cancer market is estimated to grow modestly at a CAGR of around 10.2% during the forecast period. Due to the well-established healthcare industry and awareness about bladder cancer and its treatment, the opportunities for drugs and devices for bladder cancer exist substantially in Japan. The mortality caused due to cancer in Japan is estimated to around 0.37 million in 2017. According to the Tsugane’s contribution to cancer research, the Population Attributable Fraction (PAF) of tobacco smoking to cancer was 24%, alcohol drinking was 6%, and over-intake of salt was 1.4%. The causes of the other 50% of cancer death were not sufficiently clarified.

To Request a Sample of our Report on Japan Bladder Cancer Market: https://www.omrglobal.com/request-sample/japan-bladder-cancer-market

Japan bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The cystoscopy procedure is the most used method in the diagnosis and treatment of bladder cancer. The cystoscopy uses special tools that may be passed through cystoscope to treat exceedingly small bladder tumors, which might be removed during cystoscopy. Therefore, it is highly adopted for the diagnosis of the disease.

(Get 15% Discount on Buying this Report)

A full Report of Japan Bladder Cancer Market is Available at: https://www.omrglobal.com/industry-reports/japan-bladder-cancer-market

Bladder Cancer Market Segmentation

By Cancer Type

· Transitional Cell Bladder Cancer/ Urothelial Carcinoma

· Squamous Cell Bladder Cancer

· Adenocarcinoma

· Others (Sarcomas, Carcinoma in Situ)

By Diagnosis

· Cystoscopy

· Biopsy

· Urinalysis

· Urine Cytology

· Intravenous Pyelogram (IVP)

· Others (Biomarkers)

By Treatment

· Surgery

· Chemotherapy

· Immunotherapy

· Radiation Therapy

· Others (Targeted Therapy)

Company Profiles

· Astellas Pharma Inc.

· AstraZeneca PLC

· Bayer AG

· Bristol-Myers Squibb Co.

· Eli Lilly and Co.

· F. Hoffmann-La Roche AG

· GlaxoSmithKline Plc

· Johnson & Johnson Services, Inc.

· Merck KGaA

· Pfizer Inc.

· Sysmex Corp.

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.